Beigene

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab or a placebo, along wit…

This study looks at the long-term safety of the drug zanubrutinib in people with B-cell cancers who were already in a related trial. About 955 participants will continue or start taking zanubrutinib. The main goal is to track side effects and see how well the drug controls the ca…

This study tests a new drug combination (BGB-A445 plus tislelizumab) in people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the treatment can shrink tumors and how safe it is. About 113 participants will receive the drugs, which aim to boos…

This study tests whether combining the drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors in people with advanced non-small cell lung cancer who haven't had treatment yet. About 400 adults with either high or low PD-L1 levels will tak…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants will receive either tislelizumab plus chemo or a placebo plus chemo,…

This study tests a new drug called sonrotoclax (BGB-11417) in about 125 people with mantle cell lymphoma that has come back or stopped responding to other treatments. The first part finds the safest dose, and the second part checks how well that dose shrinks tumors. The goal is t…

This study tests whether adding an experimental drug called LBL-007 to standard chemotherapy and immunotherapy can better shrink or control advanced esophageal cancer. About 118 adults with inoperable or spread esophageal squamous cell carcinoma will receive either the triple com…

This early-phase study tests a new oral drug (BGB-15025) that targets a protein called HPK1 to help the immune system fight cancer. It is given alone or with an immunotherapy (tislelizumab) to about 157 people with advanced solid tumors that have not responded to standard treatme…

This early-stage study tests a new drug called BGB-11417 in about 64 adults with certain B-cell blood cancers (like lymphoma) that have come back or not responded to prior treatments. The main goals are to find the safest dose and check for side effects. Researchers will also wat…

This study tests whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy can help people with advanced colorectal cancer that cannot be removed by surgery. About 113 participants will receive either the new combination or standard care. Th…

This study tests whether adding other drugs to tislelizumab can shrink tumors or slow cancer growth in people with advanced head and neck cancer that has come back or spread. About 160 adults whose cancer cannot be cured with local treatments will receive the drug combination as …

This phase 3 study tests whether zanubrutinib, a targeted oral drug, works better than the standard combination of bendamustine and rituximab for people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 590 participants who cannot receive…

This study tests an experimental drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who haven't gotten enough relief from standard treatments. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes …

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer who have already responded to platinum-based chemotherapy. The goal is to see if taking this pill regularly can delay the cancer from coming back. About 224 part…

This study tests different ways to start and increase the dose of sonrotoclax in adults with chronic lymphocytic leukemia (CLL). The main goal is to see if these new dosing schedules lower the risk of tumor lysis syndrome, a serious side effect. About 56 participants will be enro…

This study tests an experimental drug called BGB-11417 in 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. The goal is to see if the drug can shrink or eliminate cancer cells. Particip…

This early-stage study tests a new drug, BGB-16673, in adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger). The main goal is to check safety and how the drug moves through the body. About 34 participants will receive either the drug or a placebo, …